

Table S1. Study Inclusion and Exclusion Criteria.

Inclusion Criteria	Exclusion Criteria
– Male or female subject ≥ 18 years – Randomized < 24 hours after transplant surgery – Cold ischemia time < 30 hours – Recipient of a primary (or secondary, if first graft was not lost due to immunological reasons) kidney transplant from a deceased heart beating donor, living unrelated donor, living related non-human leukocyte antigen (HLA) identical donor, or an expanded criteria donor^a	– Use of other investigational drugs at the time of enrollment, or within 30 days or five half-lives of enrollment, whichever is longer (except for dialysis-related drugs which are not expected to interact with the study regimens) – Multi-organ transplant recipient – ABO incompatible allograft or complement-dependent lymphocytotoxic (CDC) crossmatch positive transplant – High immunological risk for rejection^b – Recipient or donor positive for HIV, hepatitis B surface antigen (HbsAg) or hepatitis C (HCV) – Body mass index (BMI) $> 35 \text{ kg/m}^2$ – Severe systemic infection (current or with 2 weeks prior to randomization) – Requirement for systemic anticoagulation that cannot be temporarily interrupted and which would preclude renal biopsy – History of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases – Severe restrictive or obstructive pulmonary disorders – Severe uncontrolled hypercholesterolemia or hypertriglyceridemia – White blood cell count $\leq 2,000 / \text{mm}^3$ or platelet count $\leq 50,000 / \text{mm}^3$ – Pregnant or nursing (lactating) women – Women of child-bearing potential, unless they are using effective methods of contraception during dosing of study treatment

^aDefined as brain-dead donor aged > 60 years or donor aged > 50 years with two of the following: history of hypertension, terminal serum creatinine $\geq 1.5 \text{ mg/dL}$ ($132 \text{ } \mu\text{mol/L}$) or death resulting from cerebrovascular accident.

^bAs determined by local practice for assessment of anti-donor reactivity e.g. high panel reactive antibodies (PRA), presence of pre-existing donor specific antigen (DSA).

Table S2. Incidence of Adverse Events and Serious Adverse Events According to Geographic Region (Safety Population).

n (%)	Everolimus	MPA	Risk Ratio (95% CI)	<i>P</i> -Value
Europe	N=521	N=490		
- Any adverse event	513 (98.5)	480 (98.0)	1.01 (0.99, 1.02)	0.544
- Any serious adverse event	319 (61.2)	305 (62.2)	0.98 (0.89, 1.08)	0.740
USA	N=169	N=179		
- Any adverse event	169 (100.0)	179 (100.0)		
- Any serious adverse event	84 (49.7)	83 (46.4)	1.07 (0.86, 1.33)	0.534
Asia	N=120	N=142		
- Any adverse event	111 (92.5)	132 (93.0)	1.00 (0.93, 1.07)	0.887
- Any serious adverse event	48 (40.0)	63 (44.0)	0.90 (0.68, 1.20)	0.476
Latin America	N=103	N=92		
- Any adverse event	103 (100.0)	89 (96.7)	1.03 (1.00, 1.07)	0.065
- Any serious adverse event	53 (51.5)	55 (59.8)	0.86 (0.67, 1.11)	0.243
Middle East	N=59	N=53		
- Any adverse event	55 (93.2)	48 (90.6)	1.03 (0.92, 1.15)	0.606
- Any serious adverse event	26 (44.1)	25 (47.2)	0.93 (0.62, 1.40)	0.742
Australia	N=42	N=56		
- Any adverse event	42 (100.0)	56 (100.0)		
- Any serious adverse event	27 (64.3)	37 (66.1)	0.97 (0.73, 1.30)	0.854

Table S3. Correlation Between Number of Wound-Related Events in Each Patient and Mean Everolimus Concentration From (i) Day 4 to Week 4, (ii) Day 4 to Month 2, and (iii) Day 4 to Month 12.

	Correlation With Everolimus Concentration Day 4 to Week 4		Correlation With Everolimus Concentration Day 4 to Month 2		Correlation With Everolimus Concentration Day 4 to Month 12	
	Rho	<i>P</i> -Value	Rho	<i>P</i> -Value	Rho	<i>P</i> -Value
Fluid collection ^a	-0.032	0.311	-0.024	0.449	-0.020	0.531
Lymphocele	0.004	0.900	0.009	0.783	0.002	0.938
Wound complications ^b	-0.038	0.226	-0.024	0.455	-0.007	0.828
Wound dehiscence	0.028	0.930	0.002	0.943	0.007	0.820
Impaired healing	-0.031	0.331	-0.022	0.484	-0.031	0.338
Wound pain ^c	-0.006	0.836	0.008	0.795	0.022	0.481

^aLymphocele, perinephric collection, post-procedural hematoma or seroma.

^bWound dehiscence, impaired healing or wound complication.

^cProcedural pain or incision site pain.

Appendix 1

The TRANSFORM Data Monitoring Committee

Alan Jardine, BHF Cardiovascular Research Centre, Glasgow, United Kingdom; Tim Friede, Department of Medical Statistics, University Medical Center Göttingen, Göttingen, Germany.

The TRANSFORM Investigators

Argentina: Rafael Maldonado, Pablo Massari, Silvina Aleman, Silvia Maurich, Luis E Gaite, Pablo Raffaele, Nora Imperiali; **Australia:** Scott Campbell, Steve Chadban, Peter Hughes, Ashley Irish, John Kanellis, Wai Lim, Philip J O'Connell, Graeme Russ, Zoltan Endre, Peter Mount; **Austria:** Paul Hengster, Peter Neudorfer, Rainer Oberbauer, Johann Pratschke; **Belgium:** Dirk Kuypers, Jean-Louis Bosmans, Emine N Broeders, Laurent Weekers; **Brazil:** Helio Tedesco Silva Jr, Elias D Neto, Valter D Garcia; **Bulgaria:** Emil P Dimitrov; **Chile:** Alvaro Kompatzki; **Colombia:** Carlos Benavides, Johanna Schweineberg; **Croatia:** Nikolina Basic-Jukic, Mladen Knotek, Sanjin Racki; **Czech Republic:** Ondrej Viklicky; **Egypt:** Mohamed Adel Bakr; **France:** Christophe Legendre, Elisabeth Cassuto, Vincent Pernin, Vincent Vuiblet, Matthias Buchler; **Germany:** Claudia Sommerer, Peter Weithofer, Thomas Rath, Oliver Witzke, Markus van der Giet, Wolfgang Arns, Lutz Renders, Antje Habicht, Daniel Seehofer, Bernhard Banas, Frank Lehner, Johann Pratschke, Rainer Oberbauer, Martin Zeier; **Greece:** Ioannis Boletis, Dimitrios Goumenos, Vasileios Papanikolaou, Spyros Drakopoulos; **India:** Dinesh Khullar, Veerbhadra Guptha, Shibu Jacob, Alan Fernandes Almeida; **Israel:** Eytan Mor, Richard Nakache; **Italy:** Mario Carmellini, Paolo Rigotti, Giacomo Colussi, Giuseppe Tisone, Paola Todeschini, Luigi Biancone, Franco Citterio, Vincenzo Cantaluppi, Loreto Gesualdo, Umberto Maggiore; **Japan:** Yoshihiko Watarai, Naotake Akutsu, Takashi Kenmochi; **Korea, Republic of:** Duck Jong Han, Myoung Soo Kim, Sung Joo Kim; **Kuwait:** Torki AlOtaibi; **Lebanon:** Dania Chelala, Hilal Abou Zeinab, Khalil Jaber; **Malaysia:** Ghazali Ahmad Kutty, Hin Seng Wong; **Mexico:** Francisco Javier Monteon Ramos; **Netherlands:** J W de Fijter, S P Berger, F J Bemelman, A D van Zuilen, L Hilbrands, M H L Christiaans; **Norway:** Anders Hartmann; **Philippines:** Romina Danguilan, Angel Joaquin Amante; **Poland:** Kazimierz Ciechanowski, Maciej Glyda, Marek Karczewski, Alicja Debska-Slizien; **Portugal:** Fernando Nolasco, Jose Guerra, Joana Santos, Patricia Joao Matias, Arnaldo Figueiredo; **Russia:** Yan G Moysyuk, Aleksey V Pinchuk, Ilya V

Aleksandrov, Vladimir E Zagainov, Elena I Boretskaya, Vladimir L Medvedev; **Saudi Arabia:** Ashraf Attia, Wael Habhab, Meteb Bugami;
Serbia: Neven Vavic, Igor Mitic, Goran Paunovic; **Singapore:** Terence Kee; **Slovakia:** Tatiana Baltesova, Eva Lackova, Zuzana Zilinska, Ivana Dedinska; **Slovenia:** Miha Arnot; **South Africa:** Elmi Muller; **Spain:** Julio Pascual, Frederic Oppenheimer, Asuncion Sancho, Alex Gutierrez Dalmau, Domingo Marrero, Josep M Cruzado, Amado Andres Belmonte, Juan Carlos Ruiz San Millan, Antonio Osuna, Ana Fernandez;
Sweden: Lars Wennberg, Bengt von Zur Muhlen, Bengt Gustafsson; **Switzerland:** Uyen Huynh-Do; **Taiwan:** Meng-Kun Tsai, Ming Ju Wu, Tsung Ching Chou; **Thailand:** Prajej Ruangkanasetr, Sakarn Bunnag, Atiporn Ingsathit; **Turkey:** Aydin Turmen, Ahmet V Celik, Huseyin Kocak; **United States:** Alexander Wiseman, Phillippe Gauthier, Fuad Shihab, Stevenson Bynon, Bernard Fischbach, Goran B Klintmalm, Richard Knight, Kenneth L Brayman, Jason Wellen, Stanley J Jordan, Yasir Qazi, Ronald Cotton, Venkat Peddi, David Leeser, Mohamed E Akoad, Shamkant Mulgaonkar, Martha Pavlakis, Reginald Gohh, Charles Bratton, Nahel Elias, Debra Sudan, Mary Waybill, Johnny Hong, Silas Norman, Ivo Tzvetanov, Dean Y Kim, Mitchell Henry, Jeffrey Rogers, Chandrasekar Santhanakrishnan, Nicolae Leca, Tomasz Kozlowski, Flavio Vincenti, Enver Akalin, Clifton E Kew, David Shaffer, Liise K Kayler, Steven Steinberg, Stuart M Flechner, Donald Hricik, Michael de Vera, Didier Mandelbrot.